1. Academic Validation
  2. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis

Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis

  • Digestion. 2002;66(4):246-56. doi: 10.1159/000068362.
Stefano Fiorucci 1 Eleonora Distrutti Andrea Mencarelli Miriam Barbanti Ernesto Palazzini Antonio Morelli
Affiliations

Affiliation

  • 1 Clinica di Gastroenterologia ed Epatologia, Dipartimento di Medicina Clinica, Sperimentale e Farmacologia, Università di Perugia, Perugia, Italy. fiorucci@unipg.it
Abstract

Background: A modification of the intestinal flora and an increased Bacterial translocation is a common finding in patients with inflammatory bowel disease as well as in animal model of colitis. Rifaximin, a non-absorbable derivative of rifamycin, is an effective Antibiotic that acts by inhibiting Bacterial ribonucleic acid synthesis.

Aims: In the present study, we investigated the effect of the administration of rifaximin (10, 30 and 50 mg/kg/day) or prednisolone (10 mg/kg/day) in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice.

Methods: Colitis was induced in mice by intrarectal administration of TNBS (1.5 mg/mouse in 50% ethanol) and disease severity assessed clinically and by histologic scoring of colon damage, determination of interleukin (IL)-2, IL-12, interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha (protein and mRNA and myeloperoxidase (MPO) activity in the colon. Cytokines production by the lamina propria mononuclear cells (LPMC) and luminal bacteria were also measured.

Results: Rifaximin administration (30 or 50 mg/kg/day) increased survival rates of colitic mice and reduced colitis severity as demonstrated by improvement of wasting syndrome, histologic scores, decrease in colon IL-2, IL-12, IFN-gamma and TNF-alpha (protein and mRNA) levels, and diminished colon MPO activity. Rifaximin administration caused a significant reduction of colon Bacterial translocation towards mesenteric lymph nodes. LPMC obtained from rifaximin-treated mice released significantly lower amount of IFN-gamma in response to ex vivo stimulation with agonistic anti-CD3 and anti-CD28 Antibodies. Rifaximin (50 mg/kg/day) significantly accelerates recovery in mice with established colitis.

Conclusions: Luminal Bacterial microflora plays a role in the pathogenesis of TNBS-induced colitis in mice. Rifaximin administration reduces the development of colitis and accelerates healing of established disease by preventing Bacterial translocation.

Figures
Products